Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
Date:8/5/2009

NEWARK, N.J., Aug. 5 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology based Life Science Company announced today independent steel corrosion test results conducted at Criterion Chemical. Following an impartial blind testing protocol Ygiene(TM) Hospital Grade Antimicrobial was found to be completely non-corrosive to steel.

Many of today's commercially available antimicrobials and cleaners are corrosive to iron and steel. As confirmed by this independent test, Ygiene(TM) Hospital Grade Antimicrobial was found to be completely inert and not corrosive while all of the following products tested were found to be corrosive: Lysol(R) Disinfectant All Purpose Cleaner 4N1; Odo Ban(R) Silver Formula Germ Control 24; Clorox(R) Anywhere Hard Surface Daily Sanitizer Spray; Lysol(R) Disinfectant Bathroom Cleaner 4N1; Clorox(R) Regular Bleach; and Green Works(TM) Natural Bathroom Cleaner. Careful steps were taken to treat all the formulations quantitatively equal to maintain standards for independent testing.

Ygiene(TM) was the only antimicrobial to show absolutely no sign of corrosion. All the other solutions exhibited clear signs of chemical reaction with the steel wool, including at least one of the following events: color change in the solution, precipitation of an undetermined substance from the solution, disintegration of the steel wool into filings, deposition on the steel wool, dissolution of the steel wool, effervescence from the steel wool or the filings.

Dr. Samuel D'Arcangelis, PhD, President of Criterion Chemical, stated: "It is truly remarkable that BioNeutral's Ygiene(TM) which contains no corrosion inhibitors was completely inert and showed no signs of corrosion in the twelve day test we conducted."

"This is an important test," said Dr. Andy Kielbania PhD, Chief Scientific Officer of Bioneutral "because of the potential for Ygiene(TM) to be used as a sterilant for medical, dental and surgical instruments as well as its use on ferrous materials which are common in the broader health care field, industrial and consumer environment. It adds a further quality to the rapid sterilizing capabilities of Ygiene(TM) which separates our technology from every competitor."

"Antimicrobials are notoriously corrosive," said Stephen J. Browand BioNeutral Group's CEO. "Commercially, there are many circumstances where a green, inert, sporicidal antimicrobial will be preferred when corrosion is a concern. As an example. medical, dental and surgical instruments are expensive and their usable life is shortened by corrosion. The pharmaceutical industry mixes basic ingredients in large stainless steel vats which can be damaged by corrosive antimicrobials."

About Criterion Chemical LLC:

Criterion Chemical is a specialty chemical company with strong expertise in understanding the reactivity of metals and the mechanism of metallic catalytic processes. In addition Criterion Chemical custom synthesizes new catalyst and has unique processes for metal recovery.

About BioNeutral:

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
5. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
6. St. Johns Hospital Acquires Latest Technology in Robotic-Assisted Surgery
7. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
8. USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
9. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
10. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
11. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... ... and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking forward to ... (PDA), the New York Interphex Show will open on March 21 and run through ... the educational and networking opportunities are extremely valuable. INTERPHEX is viewed as the key ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen Therapeutics Inc., an ... it has entered into an exclusive global license agreement with Children’s Hospital Los ... Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. ...
(Date:3/20/2017)... ... 2017 , ... The fourth annual Hackaday Prize , which aims to ... on peoples’ lives, launches today. Sponsored by Digi-Key and Microchip , ... in cash prizes to engineers, inventors and tinkerers who “build something that matters.” , ...
(Date:3/20/2017)... -- Western Institutional Review Board ® (WIRB™), the ... announced today the launch of its WIRB NIH ... multi-site research. As the long-standing leader in supporting IRB ... extensive background in reviewing clinical trials funded by NIH.  ... record for the majority of institutions that conduct clinical ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
Breaking Biology News(10 mins):